John, Luis H.
Kors, Jan A.
Fridgeirsson, Egill A.
Reps, Jenna M.
Rijnbeek, Peter R.
Article History
Received: 9 June 2022
Accepted: 15 November 2022
First Online: 5 December 2022
Declarations
:
: All patient data included in this study were deidentified.
: The New England Institutional Review Board determined that studies conducted in Optum, IBM MDCR, Iqvia Germany are exempt from study-specific IRB review, as these studies do not qualify as human subjects research.
: IMRD (study reference 21SRC025), CPRD (study reference 22_001724) and IPCI (study reference 2/2022) had institutional review board approval for the analysis, or used deidentified data, and thus the analysis was determined not to be human subjects research and informed consent was not deemed necessary at any site. IMRD incorporates data from THIN, A Cegedim Database. Reference made to THIN is intended to be descriptive of the data asset licensed by IQVIA.
: Not applicable.
: Jenna M. Reps is an employee of Janssen Research & Development and shareholder of Johnson & Johnson. Peter R. Rijnbeek, Egill A. Fridgeirsson, Luis H. John, Jan A. Kors work for a research group who received unconditional research grants from Boehringer-Ingelheim, GSK, Janssen Research & Development, Novartis, Pfizer, Yamanouchi, Servier. None of these grants result in a conflict of interest to the content of this paper.